World Wellness Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Wellness Times.

Press releases published on June 1, 2026

Jun. 1, 2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Indeterminate GlobeNewswire

Jun. 1, 2026

Spectral AI Announces Voting Results of Annual Meeting of Stockholders

Indeterminate GlobeNewswire

Jun. 1, 2026

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

Indeterminate GlobeNewswire

Jun. 1, 2026

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

Indeterminate GlobeNewswire

Jun. 1, 2026

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Indeterminate GlobeNewswire

Jun. 1, 2026

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Simply Saunas Launches as Dedicated UK Specialist for Premium Nordic Home and Garden Saunas

Indeterminate GlobeNewswire

Jun. 1, 2026

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Indeterminate GlobeNewswire

Jun. 1, 2026

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Indeterminate GlobeNewswire

Jun. 1, 2026

Vireo Growth Inc. Announces Share Consolidation

Indeterminate GlobeNewswire

Jun. 1, 2026

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Indeterminate GlobeNewswire

Jun. 1, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Jun. 1, 2026

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Indeterminate GlobeNewswire

Jun. 1, 2026

HCI Group Announces Completion of its 2026-2027 Catastrophe Reinsurance Programs

Indeterminate GlobeNewswire

Jun. 1, 2026

BriaCell Presents Positive Clinical Data at ASCO 2026

Indeterminate GlobeNewswire

Jun. 1, 2026

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Indeterminate GlobeNewswire

Jun. 1, 2026

Edible Garden Accelerates Path to Profitability Through Major Logistics Transformation, Reducing Operating Costs, Lowering Emissions and Enhancing Supply Chain Efficiency

Indeterminate GlobeNewswire

Jun. 1, 2026

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Indeterminate GlobeNewswire